55 results about "ESA Protein" patented technology

The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.

The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

The invention provides the crystal structure of the cytochrome P450 3A4 protein molecule. The structure is set out in Table 5. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related cytochrome P450 molecules.

The invention provides the crystal structure of the cytochrome P450 3A4 protein molecule. The structure is set out in Tables 1-4. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related cytochrome P450 molecules.

Disclosed are compositions and methods for detecting oral and gastrointestinal cancers in a subject. Autoantigen p90 was shown to be overexpressed in oral cancer cells, and this protein, as well as its companion autoantigen p62 and antibodies directed to both proteins, can be used as markers for detecting oral digestive and other cancers in a subject at an early stage.

The invention provides the crystal structure of the cytochrome P450 3A4 protein molecule. The structure is set out in Tables 1-4. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related cytochrome P450 molecules.

A system and method that predicts whether a given protein-ligand pair is active or inactive and outputs a pose score classifying the propriety of the pose. A 3D bioactivity platform comprising a 3D bioactivity module and data platform scrapes empirical lab-based data that a docking simulator uses to generate a dataset from which a 3D-CNN model is trained. The model then may receive new protein-ligand pairs and determine a classification for the bioactivity and pose propriety of that protein-ligand pair. Furthermore, gradients relating to the binding affinity in the 3D model of the molecule may be used to generate profiles from which new protein targets may be determined.

The present disclosure relates to the use of host cell protein biomarkers to assess disulfide bond reduction in compositions comprising a protein of interest. In some embodiments, the disclosure relates to methods of predicting the occurrence of disulfide bond reduction or low molecular weight protein species in compositions comprising a protein of interest, wherein the expression or activity level of at least one host cell protein is measured and provides a benchmark value associated with the occurrence of disulfide bond reduction or low molecular weight species of said protein of interest. In some embodiments, the disclosure relates to methods of producing a protein of interest, wherein host cells capable of producing the protein of interest are cultured, the expression or activity level of at least one host cell protein is measured, and downstream isolation of the protein of interest is informed by the host cell protein measurements.

The invention relates to a fusion protein and use thereof. The fusion protein comprises, from N to C terminals, a first moiety, an Fc segment, a linker moiety comprising a moiety selected from the group consisting of a linker and a protein or polypeptide selected from the group consisting of IL2 or scFv, and a substrate moiety of transpeptidase A; the linker comprises a sequence selected from thegroup consisting of (1) (GGGGS) n, wherein when the linker moiety comprises the protein or polypeptide and linker, n>=1; when the linker moiety only comprises the joint, n>=3; and (2) (EAAK) n, n >= 1; the substrate moiety comprises a sequence as shown in LPXTG. The fusion protein can be directly connected to cells to enable the cells to have targeting property, is simpler than an existing methodfor preparing targeting cells through cell transfection, and can also reduce the risk possibly generated by effector cell genome operation at the same time.

The invention discloses brevibacillus parabrevis as well as a method and application of a protein series prepared thereby. The classification is named as brevibacillus parabrevis GYZC01, CCTCC NO:M2011461; 16SrRNA of the brevibacillus parabrevis has a sequence of SEQ ID NO:1; the protein series prepared by the brevibacillu sparabrevis GYZC01 strain can be used for preparing thrombolytic medicine, can be used for slowly dissolving thrombus and has durability (EC50 being 200), and can be used for effectively dissolving fresh thrombus (EC50 being 400); and aiming at old thrombus, the activity ofGYZC01 strain crude protein is obviously stronger than that of urokinase (EC50 being 800).

The invention discloses a protein capable of improving salt tolerance and drought tolerance of plants as well as a coding gene and application of the protein. The protein has a sequence represented by SEQ ID NO.1 and is named as MePMP3-2. The coding gene of the protein has a sequence represented by SEQ ID NO.2 and is named as gene MePMP3-2. The protein coded by the gene MePMP3-2 is positioned in cell membranes of plants, and the coding gene MePMP3-2 of the protein is introduced into the plants, so that the germination rate of seeds of the transgenic plants under the treatment of ABA, NaCl and mannitol is increased, the root lengths and the seedling lengths of the transgenic plants under high-salinity and high-mannitol under adversities are increased, and the transgenic plants are relatively high in survival rate, relatively low in malondialdehyde (MDA) content and relatively high in proline (Pro) content under the stress of drought and high salinity; the relative expression quantities of adversity relevant genes including OsProT, OsP5CS, OsDREB2A, OsLEA3 and the like in the transgenic plants are increased at different degrees under adversity stress.

[Summary] The present invention relates to a protein production accelerating agent that has enabled to largely increase the produced amount of a desired protein by adding polysaccharides to a medium for animal cells containing a serum or serum alternative, and a production method of a protein using a medium containing the protein production accelerating agent.

With the object of providing a novel protein expression of which is specifically elevated in abnormal cells or abnormal tissue, and also providing a diagnostic method and diagnostic kit for diseases involving elevated expression of a gene encoding that protein, along with a screening method and screening kit for substances for preventing and treating diseases involving elevated expression of a gene encoding that protein, (a) a protein comprising the amino acid sequence represented by Seq. ID No. 2 or (b) a protein comprising the amino acid sequence represented by Seq. ID No. 2 with one or more amino acids deleted replaced or added is provided as a novel protein expression of which is specifically elevated in abnormal cells or abnormal tissue, with a protein expression of which is specifically elevated in abnormal cells or abnormal tissue, the level of expression of a gene encoding that protein is taken as a marker for diagnosing a disease and a reduction effect on the level of expression of a gene encoding that protein is taken as a marker for screening preventative and therapeutic substances for a disease.

The present invention relates to the field of transgenic animals. More specifically, the present invention provides methods and composition related to humanized transgenic single polymorphism non-human animal systems. In one embodiment, a system comprises (a) a transgenic non-human animal comprising a transgene encoding a wildtype human protein, wherein the protein is biologically active in the animal; and (b) at least one transgenic non-human animal comprising a transgene encoding a variant human protein, wherein the protein is biologically active in the animal and wherein the variant comprises one or more single nucleotide polymorphisms (SNPs).

The present invention relates to a protein, designated NAP (Nemo Associated Protein), that was discovered to inhibit the activation of transcription factor NF-kB by various signals that are important in inflammatory and immune processes. The DNA and the recombinant production of this protein is also disclosed as well as methods of using the protein or encoding DNA.

The present disclosure relates to a novel protein variant having an activity of exporting 5′-inosine monophosphate, a microorganism comprising the protein variant, and a method for preparing 5′-inosine monophosphate using the microorganism.